Butenafine (KP363) is a broad-spectrum benzamide antifungal agent that can inhibit the biosynthesis of ergosterol in fungi and interfere with the formation of fungal cell membranes, and can be used to prevent skin fungal infections.

Butenafine demonstrates comparable activity against the dermatophytes with a MIC range of 0.03-0.25 μg/ml. It displays limited activity against the yeast Candida albicans and no activity against Malassezia furfur[1].
Butenafine (25; 50 or 100 μM) eliminates the promastigote forms of L. amazonensis and L. braziliensis in a dose-dependent manner, and shows EC50 values of 34.10±3.76 μM and 81.25±10.24 μM, respectively, in peritoneal macrophages from BALB/c mice[1].
Butenafine induces mild cytotoxicity in peritoneal macrophages from BALB/c mice with a CC50 of 97.88 μM[1].

In primary therapeutic studies on guinea pigs, Butenafine (1% topical application; 4-10 days; day 3 and 4 post-infection) exhibits a complete cure after 10 days in vivo-effect on dermatophytosis, T. mentagrophytes[1].
Butenafine (0.125, 0.25, 0.5 and 1.0% topical application; q.d. or b.i.d. for 10 days; day 4 post-infection) exhibits a 100% cure after 0.5% or 1% application and has no difference in efficacy between 1% q.d. and b.i.d. in vivo-effect on dermatophytosis, T. mentagrophytes[1].

H2O: < 1 mg/mL (insoluble)

DMSO: Soluble, Sonication is recommended.